Pressure BioSciences (OTCQB: PBIO), a leading innovator in high-pressure nanotechnology and a pioneer in the development of novel, broadly-enabling, pressure-based instruments and nanoemulsion products and services across global industries, today announced a partnership with Vita-Forte, the largest distributor in the world of freeze-dried Acai (a potent antioxidant) to develop a highly bioavailable, multi-antioxidant oral spray. This breakthrough product is expected to be commercially available by fall 2024. “This partnership combines the strong synergistic capabilities of two companies: Vita-Forte with direct access to the highest quality oil-based antioxidant ingredients, and PBIO with the best-in-class science-based nanoemulsion processing platform,” said Richard T. Schumacher, president and CEO of PBIO. “The result of this union is expected to help establish the most effective source for both DTC and B2B customers of oil-based nutraceutical products available in the world today, starting with the release this fall of the multi-ingredient, highly bioavailable, ultrapotent antioxidant oral spray.”
To view the full press release, visit https://ibn.fm/sSCp9
About Pressure BioSciences Inc.
Pressure BioSciences is a global leader in providing innovative, broadly enabling, high pressure-based solutions for a range of industries, including biotechnology, pharmaceutical, nutraceutical, cosmeceutical, and agrochemical, as well as food and beverage manufacturing. Its patented, scalable and high-efficiency pressure-based UltraShear Technology(TM) (UltraShear(TM)) platform allows for the creation of stable nanoemulsions of otherwise immiscible oil-based active components in water. It also allows for the preparation of higher quality, homogenized, extended shelf-life or room temperature-stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies. PBIO’s patented original enabling platform, Pressure Cycling Technology (“PCT”), utilizes alternating cycles of pressure to control bio-molecular interactions (such as cell lysis and biomolecule extraction) safely and reproducibly. PCT-based products are used for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil and plant biology, forensics, and counter-bioterrorism applications. Its patented BaroFold(TM) technology platform positions the company to provide valuable contract services and GMP manufacturing equipment to the bio-pharmaceuticals industry. Its commitment to innovation and cutting-edge technology has established PBIO as a leader in the high-pressure industry, providing unique and effective solutions to its customers. For more information about the company, visit www.PressureBioSciences.com.
NOTE TO INVESTORS: The latest news and updates relating to PBIO are available in the company’s newsroom at http://ibn.fm/PBIO
About InvestorWire
InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer
InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
Editor@InvestorWire.com
InvestorWire is powered by IBN
